研究業績
Achievement

2018年以前の研究業績

1. 原著

1. Ohtani, K., Inoue, N., Hidaka, Y., and Wakamiya, N. The analysis of complement factors and activation markers in normal Japanese individuals. Hotai (Japanese) 2019; 56(2):13-22
2. H?chsmann B, Murakami Y, Osato M, Knaus A, Kawamoto M, Inoue N, Hirata T, Murata S, Anliker M, Eggerman T, J?ger M, Floettmann R, H?llein A, Murase S, Ueda Y, Nishimura JI, Kanakura Y, Kohara N, Schrezenmeier H, Krawitz PM, Kinoshita T. Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. J Clin Invest. 2019; 129(12): 5125-5136. doi: 10.1172/JCI123501. PMID:31430258
3. Morishima T, Miyashiro I, Inoue N, Kitasaka M, Akazawa T, Higeno A, Idota A, Sato A, Ohira T, Sakon M, Matsuura N. Effects of laughter therapy on quality of life in patients with cancer: An open-label, randomized controlled trial. PLoS One. 2019; 14(6):e0219065. doi: 10.1371/journal.pone.0219065. PMID: 31247017
4. Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin. Exp. Nephrol 2019; 23(1):112-121. doi: 10.1007/s10157-018-1610-2. PMID: 30039480
5. Kato, H, Miyakawa, Y, Hidaka, Y, Inoue, N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin. Exp. Nephrol. 2019; 23(1):65-75. doi: 10.1007/s10157-018-1609-8. PMID: 29959568

2. 総説